Thrombocytopenia is common in patients with myelofibrosis and is a well-established adverse prognostic factor. Both of the approved Janus kinase (JAK) inhibitors, ruxolitinib and fedratinib, can worsen thrombocytopenia and have not been evaluated in patients with severe thrombocytopenia.
Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia / Verstovsek, Srdan; Mesa, Ruben; Talpaz, Moshe; Kiladjian, Jean-Jacques; Harrison, Claire N; Oh, Stephen T; Vannucchi, Alessandro M; Rampal, Raajit; Scott, Bart L; Buckley, Sarah A; Craig, Adam R; Roman-Torres, Karisse; Mascarenhas, John O. - In: HAEMATOLOGICA. - ISSN 1592-8721. - ELETTRONICO. - (2021), pp. 1-21. [10.3324/haematol.2021.279415]
Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia
Vannucchi, Alessandro M;
2021
Abstract
Thrombocytopenia is common in patients with myelofibrosis and is a well-established adverse prognostic factor. Both of the approved Janus kinase (JAK) inhibitors, ruxolitinib and fedratinib, can worsen thrombocytopenia and have not been evaluated in patients with severe thrombocytopenia.
| File | Dimensione | Formato | |
|---|---|---|---|
|
10411-Article Text-76307-1-10-20210923.pdf
Accesso chiuso
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Tutti i diritti riservati
Dimensione
1.76 MB
Formato
Adobe PDF
|
1.76 MB | Adobe PDF | Richiedi una copia |
|
10411-Article Text-76307-3-10-20220729.pdf
accesso aperto
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Creative commons
Dimensione
463.27 kB
Formato
Adobe PDF
|
463.27 kB | Adobe PDF |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
